TipRanks
Advertisement
Advertisement

UBX Stock Latest News

Four new option listings and three option delistings on July 9th
The FlyFour new option listings and three option delistings on July 9th
1y ago
ECG
EMA
Unity Biotechnology Faces Nasdaq Delisting and Leadership Changes
PremiumCompany Announcements
Unity Biotechnology Faces Nasdaq Delisting and Leadership Changes
1y ago
8K
UBX
Unity Biotechnology Faces Nasdaq Delisting Notice
PremiumCompany Announcements
Unity Biotechnology Faces Nasdaq Delisting Notice
1y ago
8K
UBX
Leidos, SoundHound, CMC, Unity, Southwest: Trending by Analysts
PremiumWeekend Updates
Leidos, SoundHound, CMC, Unity, Southwest: Trending by Analysts
1y ago
CMC
LUV
Unity Biotechnology: Hold Rating Amid Leadership Changes and Mixed UBX1325 Study Results
PremiumRatings
Unity Biotechnology: Hold Rating Amid Leadership Changes and Mixed UBX1325 Study Results
1y ago
UBX
Unity Biotechnology downgraded to Neutral from Buy at H.C. Wainwright
PremiumThe FlyUnity Biotechnology downgraded to Neutral from Buy at H.C. Wainwright
1y ago
UBX
Unity Biotechnology downgraded to Neutral from Outperform at Mizuho
Premium
The Fly
Unity Biotechnology downgraded to Neutral from Outperform at Mizuho
1y ago
UBX
Unity Biotechnology Explores Strategic Alternatives Post-ASPIRE Study
Premium
Company Announcements
Unity Biotechnology Explores Strategic Alternatives Post-ASPIRE Study
1y ago
8K
UBX
Unity Biotechnology announces complete 36-week results from Phase 2b ASPIRE
PremiumThe Fly
Unity Biotechnology announces complete 36-week results from Phase 2b ASPIRE
1y ago
UBX
Unity Biotechnology Reports Q1 2025 Financials and Study Updates
PremiumCompany Announcements
Unity Biotechnology Reports Q1 2025 Financials and Study Updates
1y ago
UBX
Unity Biotechnology announces publication in NEJM on Phase 2 BEHOLD study
PremiumThe Fly
Unity Biotechnology announces publication in NEJM on Phase 2 BEHOLD study
1y ago
UBX
Buy Rating for Unity Biotechnology’s UBX1325: Promising Phase 2b ASPIRE Trial Data and Novel Senolytic Mechanism in DME Treatment
PremiumRatings
Buy Rating for Unity Biotechnology’s UBX1325: Promising Phase 2b ASPIRE Trial Data and Novel Senolytic Mechanism in DME Treatment
1y ago
UBX
Unity Biotechnology reports Q1 EPS (43c), consensus (40c)
PremiumThe FlyUnity Biotechnology reports Q1 EPS (43c), consensus (40c)
1y ago
UBX
Unity Biotechnology price target lowered to $4 from $8 at H.C. Wainwright
Premium
The Fly
Unity Biotechnology price target lowered to $4 from $8 at H.C. Wainwright
2y ago
UBX
Unity Biotechnology price target lowered to $4 from $6 at Chardan
Premium
The Fly
Unity Biotechnology price target lowered to $4 from $6 at Chardan
2y ago
UBX
Positive Outlook for Unity Biotechnology Despite Initial Setback in UBX1325 Study
PremiumRatings
Positive Outlook for Unity Biotechnology Despite Initial Setback in UBX1325 Study
2y ago
UBX
Unity Biotechnology announces results from ASPIRE Phase 2b study in DME
PremiumThe Fly
Unity Biotechnology announces results from ASPIRE Phase 2b study in DME
2y ago
UBX
Unity Biotechnology Appoints Dr. Yehia Hashad to Board
PremiumCompany Announcements
Unity Biotechnology Appoints Dr. Yehia Hashad to Board
2y ago
8K
UBX
Unity Biotechnology appoints Hashad to board of directors
PremiumThe Fly
Unity Biotechnology appoints Hashad to board of directors
2y ago
UBX
Buy Rating Reaffirmed for Unity Biotechnology Amid Promising Developments in DME Treatment
PremiumRatingsBuy Rating Reaffirmed for Unity Biotechnology Amid Promising Developments in DME Treatment
2y ago
UBX
Unity Biotechnology Reports 2024 Financial Results and Updates
Premium
Company Announcements
Unity Biotechnology Reports 2024 Financial Results and Updates
2y ago
UBX
Unity Biotechnology reports Q4 EPS (50c) vs. (28c) last year
Premium
The Fly
Unity Biotechnology reports Q4 EPS (50c) vs. (28c) last year
2y ago
UBX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >